June 25, 2010 (FinancialWire) (Go to http://www.financialwire.net/?s=ftrdnwswnd for all of today’s featured news.) — Bioniche Life Sciences Inc. (TSX: BNC), a Canadian biopharmaceutical firm, and Trophogen Inc., a U.S.-based biotechnology firm, have signed an exclusive global veterinary license agreement between the two companies.

The agreement provides commercial access for Bioniche to a patented, proprietary superagonist hormone technology platform developed by Trophogen (originally licensed from the National Institutes of Health) in the veterinary fields.

For the past 12 months, Bioniche has been evaluating the technology in field situations and has gained confidence in its capabilities in reproductive enhancement.

According to the companies, the technology will initially be developed into a next generation follicle stimulating hormone. The company's current FSH product is Folltropin-V. Folltropin-V is used to superovulate reproductively mature cattle.

Bioniche also holds an option to license additional veterinary reproductive products utilizing Trophogen's superagonist hormone technology.

Canada-based Bioniche Life Sciences is focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide.

Maryland-based Trophogen was founded in 2001 with series A funding from Toucan Capital, focusing on the development of high affinity glycoprotein hormone and related growth factor analogs for human and animal infertility as well as targeted therapy and imaging of thyroid, ovarian, breast, prostate and testicular cancers.

Trophogen was formed by two molecular endocrinologists who spent years as academicians at the National Institutes of Health and the University of Maryland before striking out on their own to launch their first entrepreneurial endeavor.

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://investrend.stocksmart.com/ss/html/hpcompany.html). Current valuation analysis research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://www.valuengine.com/rep/searchsrep?pid=42&srchfor=).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public other companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation from subject entities, companies, equities, or representatives thereof, for its news, opinions or distributions. Further disclosure is posted at the FinancialWire(tm) website (at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Copyright © MMX, FinancialWire(tm); All rights reserved.

[hlmsmlh] [biomedphrm] [nwdlsldw] [ntrntnlcmpnsbsnss] [cndnexh] [ntrntnlcmpnsbsnss] [agrcltrtlc] [frmrnchcmrf] [ftrdnwswnd]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.